Fluoroscopy-guided biodegradable spacer implantation using local anesthesia: safety and efficacy study in patients with massive rotator cuff tears by unknown
ORIGINAL ARTICLE
Fluoroscopy-guided biodegradable spacer implantation using
local anesthesia: safety and efficacy study in patients with massive
rotator cuff tears
E. Gervasi1 • E. Maman2 • A. Dekel3 • E. Cautero1
Received: 1 May 2016 / Accepted: 14 October 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Background The management of massive rotator cuff
tears (MRCTs) is challenging and associated with a high
failure rates. Studies have shown that advanced age, lower
American Society of Anesthesiologists physical status
score and concomitant comorbidities are associated with
higher risks of death and postoperative complications. This
study was designed to assess the safety and efficacy of
fluoroscopy-guided biodegradable spacer implantation
under local anesthesia, in patients with MRCT and
comorbidities completely or partially contraindicating
surgeries under general anesthesia.
Methods In this open-label, single arm, prospective study,
subjects with MRCTs underwent subacromial fluoroscopy-
guided implantation with a biodegradable spacer (InS-
paceTM system) under local anesthesia. Fifteen patients
were treated and assessed. Follow-up visits were scheduled
according to routine clinical practice. Shoulder function
was evaluated using Constant (CS) and American Shoulder
and Elbow Society (ASES) scores.
Results All patients demonstrated an overall improvement
in the total CS and ASES beginning at 6 weeks and sus-
tained by at least 12 months postoperatively. Of the 15
patients who reached the 1-year follow-up, 85% showed a
clinically significant improvement of at least 15 points in
their Constant score starting at 6 weeks postoperation and
maintained throughout the entire follow-up period.
Conclusions We conclude that in this initial patient’s
cohort, fluoroscopy-guided implantation of InSpaceTM
system under local anesthesia, represented an effective
alternative to the existing procedures. This procedure may
be considered as a treatment option for elderly patients or
for patients with multiple comorbidities complicating or
contraindicating surgery under general anesthesia. Tech-
nically easy, this technique can be an effective tool in the
armamentarium of most orthopedic surgeons. Level of
proof: single-arm prospective study, Level II.
Keywords Massive rotator cuff tears  Local anesthesia 
Biodegradable spacer  Fluoroscopy-guided subacromial
implantation
Background
The management of patients with massive rotator cuff tears
(MRCT) remains a challenge for orthopedic surgeons. In
complex MRCT cases, treatment options are often limited
to total shoulder arthroplasty or tendon transfer. To date,
only few non-arthroplasty surgical options exist for the
treatment of MRCTs. In cases of complex, non-repairable
MRCT, the choices are: tendon transfers for active patients
and shoulder reverse arthroplasty for the eldest or when
arthritic changes involve the joint. Open or arthroscopic
debridement of the RCT and acromioplasty may be appro-
priate for low-demand patients [1–4]. In cases where pain
originates from the humeral head, biceps tenotomy is
applicable [5]. Several studies have shown mixed results
regarding RC augmentation with allografts or extracellular
matrix scaffolds [6, 7]. Patients presenting with marked
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weakness and pain but without glenohumeral arthritis in the
setting of IRCT may benefit from a tendon transfer [8, 9].
Nevertheless, there is no current consensus or definitive
guidelines concerning the optimal surgical treatment for
this devastating condition.
Studies in many orthopedic fields such as hip and spine
surgery have shown that advanced age, lower American
Society of Anesthesiologists (ASA) physical status score
[10], concomitant cardiovascular disease, pulmonary dis-
ease and diabetes are associated with higher risks of death
and postoperative complications [11, 12].
Vast majority of the patients with MRCT belong to the
same age group and might suffer from the similar diseases;
thus, one could assume that the relative risk of death and
postoperative complications will be as high as in the
aforementioned fields. Regional (local) anesthesia is
therefore believed to decrease postoperative complications
by reducing sympathetic activation and inflammation, by
preventing venous stasis, and by avoiding tracheal intu-
bation and positive pressure ventilation [13, 14].
Regional anesthesia for upper limb surgery has several
advantages compared with general anesthesia, including
better postoperative analgesia, less nausea and vomiting,
more hemodynamic stability, fewer side effects and a
favorable complications profile [15]. However, the so-
called blended anesthesia that includes interscalene nerve
block adjunct to the general anesthesia is the common
choice for shoulder surgery.
The latest treatmentmodality suggested forMRCT patients
is the InSpaceTM system [16, 17]. This device is a biodegrad-
able spacer (balloon shape), which is implanted between the
acromion and the humeral head and helps to recenter the
humeral head relative to the glenoid. The spacer is made of a
copolymer poly (L-lactide-co-e-caprolactone) that is
biodegradable and totally dissipates within 12 months of
implantation. The device attempts to restore painless shoulder
biomechanics by decreasing subacromial friction and by
lowering the humeral head during abduction [17]. The biode-
gradable spacer may be implanted under local anesthesia.
Local anesthesia alone for the fluoroscopy-guided InSpace
implantation does not require low systolic blood pressure
maintenance as compared to the other arthroscopic procedures.
Patients with chronic progressive RC tears often
develop the ability to compensate for their deficient RC
without even being aware of this learned behavior. By
inserting this biodegradable spacer, the shoulder is enabled
to potentially learn this compensatory behavior, thus
allowing the patient to develop a chronic compensated and
asymptomatic RC tear-type shoulder. During this period,
the device permits the humeral head to glide smoothly
without friction under the acromion, thus permitting
longstanding improvement in glenohumeral joint motion
with significant pain reduction.
This study aimed to assess the safety and efficacy of the
InSpace implantation under local anesthesia in patients
with multiple comorbidities, contraindicating more inva-
sive surgeries, such as reverse arthroplasty, within a period
of at least one year following the surgery.
Patients and methods
The Udine Regional Ethics Committee (Italy) reviewed
and approved the study, and each of the participating
patients gave their written consent as required prior to any
study procedure. In the first cohort of the study, fifteen (15)
patients including 8 (53%) females and 7 (47%) males with
a mean age 74.6 (SD: 6.5; Median: 23.7) (Table 1) met the
inclusion criteria and were enrolled. The criteria for
inclusion were age 50 years or older, imaging confirmation
of a RCT by MRI and documented failure of conservative
therapy. Patients with evidence of significant osteoarthritis,
or cartilage damage in the shoulder, significant gleno-
humeral instability, major joint trauma, infection or
necrosis in the shoulder were excluded. Patient demo-
graphic information, non-orthopedic comorbidities, type
and severity of the shoulder injury, pain level and baseline
physical function were recorded.
All patients were symptomatic and complained of per-
sistent shoulder pain for a minimum of 4 months. The
mean period from first complaint of shoulder pain to
operation was 47 months (SD: 60.5, Median: 16.6), while
the time from diagnosis up to surgery was 7 months
(SD:4.7, Median 6.6) (Table 1).
All patients had previously failed RC syndrome treat-
ments such as steroid injections and physiotherapy. Of
these, 5/15 (33%) had been previously treated surgically
with either cuff repair or debridement and biceps tenotomy.
Table 1 Baseline patients’ characteristics
Age 74 ± 6
Gender (female/male) 8/7
Dominant arm involved (yes/no) 11/4
VAS pain scale (0–10) 7.1 ± 1.6
Total ASES (0–100) 24.5 ± 14
Total CS (0–100) 31.9 ± 14
Fatty infiltration (III/IV)a 6/9
Previous conservative treatment: steroid
injection/pain medication/PT
10/2/3
Prior surgery of rotator cuff (yes/no) 5/10
Time from RCT diagnosis till operation 7 ± 4.6 months
Values are expressed as mean ± standard deviation or in number of
patients
a Fatty degeneration is classified according to modified Goutallier
et al. [21] as diagnosed by baseline MRI
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The mean preoperative visual analogue scale (VAS) for
pain was 7.1, and the mean TCS and ASES were 31.9 and
24.5, respectively.
Surgical procedure
All procedures were performed by two, fellowship-trained
shoulder surgeon (EG and EC). Briefly, implantations were
performed utilizing fluoroscopy procedure with the patient
seated in either a beach-chair position or lateral decubitus
position, under local anesthesia and fluoroscopic guidance
as was previously described [18].
The local anesthesia was performed first, by injecting
Lidocaine 2% and Marcaine 2% into the subacromial
space, at the lateral incision situ and around the antero-
lateral acromion edge.
A lateral incision 1.5 cm long matches the lateral
arthroscopic portal. The device implantation proceeds by
inserting two identical metal rods, verified under fluoro-
scopic vision, until it overhangs 1 cm medially the glenoid
rim. The proper position was verified using the fluoroscopy
(coronal and axial view) (Fig. 1a). The outside part of the
rod was measured to indicate the needed spacer size (small,
medium or large).
The device implantation was completed by inserting the
protecting sheath until it was 1 cm medial to the glenoid
rim, while following the direction of the scapular spine (to
avoid too anterior or posterior position). Correct position
was verified using a lateral fluoroscopy view (Fig. 1b).
At this stage, we preferred to push the protecting sheath
over the rod; while the sheath was in place, the rod was
retracted and replacedby the rolled spacer (balloon).This ‘‘out
of the role’’ maneuver with the rod, that does not bend, allows
maintaining the right position during the whole insertion.
Once the position is assured, the device is inflated using
physiological solution: at the maximum filling volume first,
to spread the spacer, then the volume reduced to the rec-
ommended value by withdrawing a definite amount of the
solution, as per each device size-specific instructions in the
product labeling.
The spacer (balloon) is then sealed and secured in situ;
the delivery system removed and the skin closed. The
humeral head position and the acromion-humeral distance
increase are confirmed by fluoroscopy, determining the
accurate placement of the implant (Fig. 1c).
Outcome measures
The same orthopedic surgeon (E.C.) assessed the pre- and
postoperative shoulder function at each visit until the ‘‘two
years’’ postimplantation follow-up. Physical examination,
ROM and shoulder function were assessed by Constant
score (CS) and American Shoulder and Elbow Society
(ASES) [19] evaluated postoperatively at the following
time points: 2, 6 weeks, 3, 6, 12 and 24 month. Primary
outcomes were defined as final total functional scores
(Constant and ASES scores).
Ultrasound was done to all patients up to 3 months
postimplantation to verify device positioning.
Statistical analysis
Study data were analyzed with the SAS version 9.2 (SAS
Institute, Cary NC, USA). For comparison of means
(continuous variables), the two-sample t test or the Wil-
coxon rank sum test were used. For comparison of pro-
portions (categorical variables), the Chi-squared test or
Fisher’s exact test was as appropriate. The mean changes
from baseline in total CS and adjusted CS and its subscales
were determined using a repeated measures analysis vari-
ance model. p values\0.05 were considered statistically
significant with no adjustment for multiple testing.
Results
Fifteen patients were treated and assessed. This patients
group demonstrated an overall statistically and clinically
significant improvement in the total CS andASES beginning
at 6 weeks and sustained by 24 months postoperatively.
Fig. 1 Fluoroscopy-guided implantation of subacromial biodegradable spacer. a Subacromial space measurement. b Confirmation of device
insertion by fluoroscopic view. c Confirmation of placement
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Of the 15 patients that completed a minimum of 1-year
follow-up, 80% presented good effectiveness results,
including rapid pain relief and restoration of active and
painless motion and improvement of at least 10 points in
the total Constant score (TCS) starting at 6 weeks
postimplantation, which maintained over time. Ten (10) of
these patients (66.6%) also completed 2 years of postop-
erative follow-up in which the improvement in shoulder
functionality and pain was sustained.
The total CS has improved significantly from a mean of
31.9 point at preoperative (baseline) to 69.8 points at
12-month postoperation and maintained at the similar
improvement level for 70% of the ten patients that com-
pleted the 24-month follow-up (Fig. 2).
The ASES score has improved significantly (pre-
op/post-op (12 m/24 m): pain (VAS) 7.1/1.4/2.1; ADL 6.1/
19.3/19.8 TOTAL 24.5/76/72.5) (Fig. 3). Majority of
patients (13/15, 80%) were scored their satisfaction of the
surgical procedure as 8–10 (in a scale on 0–10, where 10 is
very satisfied).
Pain parameters of both CS and ASES (VAS) as well
as ROM improved significantly (p B 0.005) starting
2-week postimplantation procedure, while other shoul-
der parameters (ADL, ROM and had power/strength)
had improved starting 6-week postimplantation (Figs. 2,
3, 4).
All patients beside two (20%) were discharged at the
same day of the surgery and did not complained of any
postoperative effect such as nausea and vomiting or
hemodynamic instability. The two patients that remained
overnight stayed either due to their elderly age that
required closer observation or due to the distance from
hospital to home that required overnight stay.
Mean implantation time was of the device was
approximately 10 min.
The device implantation time ranged from 5 min in 28%
of the procedures to 20 min in 5% of the cases when the
surgeon faced some technical constrains. Device was rated
as very easy for use by the surgeon with a mean score of
8.7 in a scale of 1–10 (where 1 is very difficult and 10 is
very easy to deploy and operate).
During the postoperative period, no serious or clinically
significant device-related adverse effects were observed.
Only one patient (1/25; 0.4%) prematurely discontinued his
participation in the study at 6-month postimplantation due
to insufficient improvement and was referred to a shoulder
arthroplasty.
Discussion
The principal results of this study demonstrated a signifi-
cant improvement in the shoulder function in patients with
MRCTs following fluoroscopy-guided implantation of the
InSpaceTM system under local anesthesia. One-year follow-
up revealed a significant improvement in the total CS and
ASES (including pain scores, nocturnal pain, range of
movement and activity of daily living) commencing at the
early postoperative stages, and continued with further
improvement throughout prolonged follow-up.
This study results are in a line with those reported by
Senecovic et al. [15]. Senecovic et al. reported a significant
increase in the mean total CS from 33.4 to 65.4 points at
3 years. There was an improvement of 6.4 points in sub-
jective pain score, which commenced at 1 week postop-
eratively and was sustained until 3 years of follow-up.
Improvement in power was only evident at 18 months of
follow-up but was sustained at 3 years.
Efficacy results of the current study are comparable with
those reported in a series of patients treated with existing
Fig. 2 Graphical presentation
of Constant variables following
biodegradable spacer insertion.
Values are presented as
mean ± SD
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techniques. Rockwood et al. [4] reported 83% satisfactory
results using debridement, subacromial decompression and
acromioplasty of massive degenerative IRCTs with an
average follow-up of six years. Arthroscopic repair of mas-
sive rotator cuff tears with stage 3 and 4 fatty infiltrations
resulted in significant functional improvement as reported by
Burkhart et al. [20]. With mean follow-up of 39 month,
Burkhart et al. demonstrated a clinical improvement for
some patients having[75% fatty degeneration and for all
patients in the 50–75% group. Current study suggests a less
invasive surgical procedure that can be done in an outpatient
clinic using local anesthesia.
Nevertheless, the main limitation of this study is the
small number of patients with a relatively short follow-up
period. As the initial protocol was intended to observe the
outcome of such challenging patients’ population, the study
sample size was increased to 45 patients in order to present
more powerful and statistically significant efficacy out-
come. Also the fact that the study has no comparative arm
is a downside; however, the selected patients were failed
the common treatment of MRCT and more than 30% of
them failed a combination of both surgical intervention and
conservative treatment. Hence, we believe that at this
specific indication, there is no suitable comparative arm
and it is appropriate to use each patient as its own control,
the mentioned extension of the study to 45 subjects will
overcome this challenge.
In summary, the data strongly suggest that fluoroscopy-
guided InSpace implantation under local anesthesia is a low-
risk, clinically effective option, especially for the elderly
Fig. 3 Graphical presentation
of total ASES score following
biodegradable spacer insertion.
Values are presented as
mean ± SD
Fig. 4 Graphical presentation
of VAS obtained from ASES
score. Values are presented as
mean ± SD
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population and those patients suffering for multiple comor-
bidities or with contraindication to general anesthesia. It can
be alternative to the reverse prosthesis or to tendon transfers
in patients with MRCTs without arthropathy.
The procedure of insertion of the InSpace under local
anesthesia can be carried out in a day-care or outpatient
setting; it is technically easy. This last aspect gives a
chance to patients living in areas where the shoulder sur-
gery is still developing.
Since currently there are neither consensus nor guide-
lines for the best surgical option in this MRCTs challeng-
ing patient population, we conclude that fluoroscopy-
guided InSpace implantation is an effective alternative to
the existing procedures, arthroscopic or open, for patients
having painful massive rotator cuff tears refractory to
surgical or conservative managements. A controlled trial
with larger cohort of subject for longer follow-up period
for the clinical and functional outcomes following fluo-
roscopy-guided InSpace TM implantation will further
establish the results and outcome of this initial study
cohort.
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